A dosing volume is not simply a species-based number. In a preclinical pharmacokinetic (PK) study, the volume has to deliver the intended dose at a feasible concentration while staying appropriate for the administration route, formulation, dosing schedule and animal. Published volume tables help with early planning, but they do not replace protocol-specific veterinary and ethical review.
Planning an NHP or other large-animal PK study? Discuss your dosing and sampling plan with Prisys Biotech. Include the intended species, route, dose range and what is known about solubility; a final formulation is not needed to start a discussion.
How do you calculate dosing volume and concentration?
The three quantities are linked:
- Dosing volume (mL/kg) = target dose (mg/kg) ÷ formulation concentration (mg/mL)
- Required concentration (mg/mL) = target dose (mg/kg) ÷ planned dosing volume (mL/kg)
- Volume per animal (mL) = dosing volume (mL/kg) × body weight (kg)
For example, a 25 g mouse receiving 10 mg/kg by oral gavage at an illustrative volume of 10 mL/kg would receive 0.25 mg in 0.25 mL. The formulation concentration would be 1 mg/mL. For three animals of that weight, 0.75 mg is the theoretical amount delivered, not the amount to order or prepare. Preparation losses, dosing-device dead volume, formulation checks, repeat dosing, analytical standards and quality-control samples increase material requirements.
For IV dosing, use the actual IV volume approved for that protocol, not the oral gavage volume. If a study proposes 1 mg/kg in 5 mL/kg, the arithmetic gives 0.2 mg/mL; whether that volume, rate and formulation suit the specific animal and IV procedure is a separate decision. Do not transfer a volume from one route or species to another without review.
What determines a suitable dosing volume?
Start with the proposed route and study objective, then confirm that the required concentration is achievable and reproducible. Key questions include:
| Decision point | What to check before dosing |
|---|---|
| Species and animal status | Body weight, age, health, disease model and any route-specific welfare considerations. |
| Route and administration | Oral gavage versus IV bolus or infusion; injection site, equipment, infusion rate and frequency of administration. |
| Formulation | Solubility at the intended concentration, pH, osmolality, viscosity, excipient tolerability and short-term stability. |
| PK readout | Whether the vehicle or the administration procedure alters absorption, exposure or the interpretation of sampling data. |
| Study governance | The approved protocol, institutional veterinary advice and applicable animal-care requirements. |
A familiar mL/kg value is therefore a starting assumption, not a universal maximum or an authorization to dose. Increasing the volume to compensate for poor solubility raises welfare concerns and complicates PK interpretation. Reducing volume raises the concentration requirement and exposes precipitation, viscosity or delivery problems. Both directions need a formulation feasibility check.
Oral versus intravenous administration
Oral gavage planning should consider the physical volume delivered, repeat-dose frequency and the effects of the vehicle on gastrointestinal tolerability and absorption. IV planning adds route-specific concerns such as injection or infusion rate, vascular access, local irritation, compatibility and the possibility of precipitation after dilution in blood. The same candidate therefore needs different formulations and volumes for the PO and IV arms.
When the study involves non-human primates
NHP protocols deserve a project-level decision rather than a copied rodent or dog table. The route, restraint or anaesthesia plan, infusion method, dosing frequency and sampling schedule belong together with formulation tolerability. Prisys Biotech describes in vivo PK capabilities in cynomolgus macaques, dogs and minipigs, as well as selected specialized delivery and biofluid or tissue sampling approaches. The suitability and availability of any particular procedure should be confirmed for the proposed study.
If dose, concentration and practical NHP volume do not align, contact Prisys to discuss feasibility before finalizing the protocol. This matters most when the candidate has limited solubility, the intended route is specialized, or serial PK sampling is required.
Why do pH and excipients matter as much as volume?
Adjusting pH raises the apparent solubility of an ionizable compound, but a solution that looks clear in a vial sometimes precipitates after dilution or on exposure to physiological conditions. Extreme pH, unsuitable osmolality and irritating excipients affect tolerability and confound PK results. No single safe pH interval or solvent percentage applies to every species and route.
Before a formulation is selected, check solubility at the target concentration; pH and buffer capacity; osmolality and viscosity where relevant; stability over the preparation and dosing window; and compatibility with the delivery device and analytical assay. For IV dosing, pay particular attention to compatibility on dilution and route-specific safety. For PO dosing, consider whether the vehicle or a suspension shifts exposure or variability. Vehicle-only controls and documentation of preparation conditions help interpret findings, subject to the study design.
These checks are most valuable before treating a higher volume as the answer. A change in route, concentration, formulation strategy or study design is often more appropriate, but each option needs review on scientific and animal welfare grounds.
What information helps a CRO assess dosing feasibility?
A concise project outline turns a general question about mL/kg into a useful feasibility discussion. If available, share:
- Species, body-weight range and relevant disease model.
- Intended route, target dose levels and dosing schedule.
- Known solubility, proposed vehicle, pH or stability constraints.
- Available test-article amount and any formulation or bioanalytical data.
- PK endpoints, sampling time points and whether tissue or specialized biofluid sampling is needed.
Prisys Biotech provides PK study services and describes ADME and bioanalysis capabilities. These details help the team discuss whether the proposed dosing approach and analytical plan fit the project; they are not a substitute for protocol approval or formulation qualification.
Frequently asked questions
Q: Is 10 mL/kg suitable for every animal PK study?
A: No. A volume used in one illustrative rodent oral-gavage example is not a universal target or maximum. Route, species, animal status, vehicle, concentration and institutional approvals belong together.
Q: What if the required concentration exceeds measured solubility?
A: Do not assume that adding volume is the answer. Assess solubility and stability in the proposed vehicle, then consider whether a different formulation, dose level, route or study design is scientifically justified and acceptable under the approved protocol.
Q: How much test article should be supplied for a PK study?
A: Calculate the theoretical administered mass first, then add material needed for preparation losses, extra animals or repeat dosing, formulation characterization and bioanalytical calibration or quality controls as applicable. Dose and group size alone do not give a fixed milligram estimate.
Discuss your PK dosing plan
If you are planning an NHP or other large-animal study and need to reconcile dose, volume, formulation and sampling requirements, contact Prisys Biotech or email bd@prisysbiotech.com. A brief outline with the five items above is enough to frame an initial discussion; do not send confidential compound details until an appropriate disclosure process is agreed.
Further reading: Diehl et al., 2001, good practice guide to administration routes and volumes; Turner et al., 2011, administration routes and factors to consider; Turner et al., 2011, vehicle selection and solute preparation. These sources provide general principles; the governing approved protocol takes precedence for an individual study.
